Observational study of small animal practitioners’ awareness, clinical practice and experience with faecal microbiota transplantation in dogs

2022 ◽  
pp. 100630
Author(s):  
S. Salavati Schmitz
Keyword(s):  
Clinical Practice ◽  
Observational Study ◽  
Small Animal ◽  
Faecal Microbiota ◽  
Faecal Microbiota Transplantation

scholarly journals Faecal microbiota transplantation in clinical practice

Gut ◽  
2017 ◽  
Vol 67 (1) ◽  
pp. 196.1-196 ◽  
Author(s):  
E M Terveer ◽  
Y H van Beurden ◽  
A Goorhuis ◽  
C J J Mulder ◽  
E J Kuijper ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Faecal Microbiota ◽  
Faecal Microbiota Transplantation

scholarly journals Faecal microbiota transplantation in clinical practice

Gut ◽  
2017 ◽  
Vol 67 (1) ◽  
pp. 196.2-197 ◽  
Author(s):  
Giovanni Cammarota ◽  
Gianluca Ianiro ◽  
Antonio Gasbarrini
Keyword(s):  
Clinical Practice ◽  
Faecal Microbiota ◽  
Faecal Microbiota Transplantation

scholarly journals International consensus conference on stool banking for faecal microbiota transplantation in clinical practice

Gut ◽  
2019 ◽  
Vol 68 (12) ◽  
pp. 2111-2121 ◽  
Author(s):  
Giovanni Cammarota ◽  
Gianluca Ianiro ◽  
Colleen R Kelly ◽  
Benjamin H Mullish ◽  
Jessica R Allegretti ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Ethical Issues ◽  
Consensus Conference ◽  
Faecal Microbiota ◽  
International Consensus ◽  
Face To Face ◽  
Faecal Microbiota Transplantation ◽  
Clostridioides Difficile

Although faecal microbiota transplantation (FMT) has a well-established role in the treatment of recurrent Clostridioides difficile infection (CDI), its widespread dissemination is limited by several obstacles, including lack of dedicated centres, difficulties with donor recruitment and complexities related to regulation and safety monitoring. Given the considerable burden of CDI on global healthcare systems, FMT should be widely available to most centres.Stool banks may guarantee reliable, timely and equitable access to FMT for patients and a traceable workflow that ensures safety and quality of procedures. In this consensus project, FMT experts from Europe, North America and Australia gathered and released statements on the following issues related to the stool banking: general principles, objectives and organisation of the stool bank; selection and screening of donors; collection, preparation and storage of faeces; services and clients; registries, monitoring of outcomes and ethical issues; and the evolving role of FMT in clinical practice,Consensus on each statement was achieved through a Delphi process and then in a plenary face-to-face meeting. For each key issue, the best available evidence was assessed, with the aim of providing guidance for the development of stool banks in order to promote accessibility to FMT in clinical practice.

scholarly journals European consensus conference on faecal microbiota transplantation in clinical practice

Gut ◽  
2017 ◽  
Vol 66 (4) ◽  
pp. 569-580 ◽  
Author(s):  
Giovanni Cammarota ◽  
Gianluca Ianiro ◽  
Herbert Tilg ◽  
Mirjana Rajilić-Stojanović ◽  
Patrizia Kump ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Consensus Conference ◽  
Faecal Microbiota ◽  
Faecal Microbiota Transplantation ◽  
European Consensus

Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice

Gut ◽  
2020 ◽  
Vol 69 (5) ◽  
pp. 801-810 ◽  
Author(s):  
Craig Haifer ◽  
Colleen R Kelly ◽  
Sudarshan Paramsothy ◽  
David Andresen ◽  
Lito E Papanicolas ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Evaluation System ◽  
Future Research ◽  
Faecal Microbiota ◽  
Faecal Microbiota Transplantation ◽  
Minimum Standards ◽  
Delphi Approach ◽  
Clinical Indications ◽  
Consensus Statements ◽  
Treatment Facilities

ObjectiveFaecal microbiota transplantation (FMT) has proved to be an extremely effective treatment for recurrent Clostridioides difficile infection, and there is interest in its potential application in other gastrointestinal and systemic diseases. However, the recent death and episode of septicaemia following FMT highlights the need for further appraisal and guidelines on donor evaluation, production standards, treatment facilities and acceptable clinical indications.DesignFor these consensus statements, a 24-member multidisciplinary working group voted online and then convened in-person, using a modified Delphi approach to formulate and refine a series of recommendations based on best evidence and expert opinion. Invitations to participate were directed to Australian experts, with an international delegate assisting the development. The following issues regarding the use of FMT in clinical practice were addressed: donor selection and screening, clinical indications, requirements of FMT centres and future directions. Evidence was rated using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system.ResultsConsensus was reached on 27 statements to provide guidance on best practice in FMT. These include: (1) minimum standards for donor screening with recommended clinical selection criteria, blood and stool testing; (2) accepted routes of administration; (3) clinical indications; (4) minimum standards for FMT production and requirements for treatment facilities acknowledging distinction between single-site centres (eg, hospital-based) and stool banks; and (5) recommendations on future research and product development.ConclusionsThese FMT consensus statements provide comprehensive recommendations around the production and use of FMT in clinical practice with relevance to clinicians, researchers and policy makers.

scholarly journals Diseases Associated with Disturbed Intestinal Microbiota

Doctor Ru ◽  
2021 ◽  
Vol 20 (4) ◽  
pp. 40-45
Author(s):  
V.O. Kaibysheva ◽  
◽  
M.E. Zharova ◽  
K.Yu. Filimendikova ◽  
E.L. Nikonov ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Type 2 Diabetes ◽  
Clinical Practice ◽  
Intestinal Microbiota ◽  
Faecal Microbiota ◽  
Faecal Microbiota Transplantation ◽  
Additional Information ◽  
Key Points ◽  
Autistic Disorders

Objective of the Review: To discuss changes in intestinal microbiota in various diseases. Key Points. Microbial intestinal imbalance plays an important role in pathogenesis and/or progression of a number of diseases, namely of Clostridium difficile-associated disorders, intestinal inflammations, obesity, colorectal cancer, autistic disorders and other. Moreover, therapies involving faecal microbiota transplantation, use of pro- and prebiotics, metabiotics proved efficient in management of some of the above disorders. Conclusion. So far, some mechanisms have been explored which explain possible participation of intestinal microbiota in pathogenesis of colorectal cancer, intestine inflammation, type 2 diabetes milletus, and hepatic disorders. Still, additional information is required to allow using available facts in clinical practice. Keywords: microbiota, microbiome, faecal microbiota transplantation, probiotics.

scholarly journals Health economic evaluations comparing faecal microbiota transplantation with antibiotics for treatment of recurrent Clostridioides difficile infection: a systematic review

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Lianna Hede Hammeken ◽  
Simon Mark Dahl Baunwall ◽  
Christian Lodberg Hvas ◽  
Lars Holger Ehlers
Keyword(s):  
Health Economic ◽  
Clinical Practice ◽  
Cost Saving ◽  
Antibiotic Treatment ◽  
Cost Effective ◽  
Economic Evaluations ◽  
Faecal Microbiota ◽  
Faecal Microbiota Transplantation ◽  
Clostridioides Difficile

Abstract Background Faecal microbiota transplantation (FMT) is increasingly being used in the treatment of recurrent Clostridioides difficile infection (rCDI). Health economic evaluations may support decision-making regarding the implementation of FMT in clinical practice. Previous reviews have highlighted several methodological concerns in published health economic evaluations examining FMT. However, the impact of these concerns on the conclusions of the studies remains unclear. Aims To present an overview and assess the methodological quality of health economic evaluations that compare FMT with antibiotics for treatment of rCDI. Furthermore, we aimed to evaluate the degree to which any methodological concerns would affect conclusions about the cost-effectiveness of FMT. Methods We conducted a systematic literature review based on a search in seven medical databases up to 16 July 2020. We included research articles reporting on full health economic evaluations comparing FMT with antibiotic treatment for rCDI. General study characteristics and input estimates for costs, effectiveness and utilities were extracted from the articles. The quality of the studies was assessed by two authors using the Drummonds ten-point checklist. Results We identified seven cost-utility analyses. All studies applied decision-analytic modelling and compared various FMT delivery methods with vancomycin, fidaxomicin, metronidazole or a combination of vancomycin and bezlotoxumab. The time horizons used in the analyses varied from 78 days to lifelong, and the perspectives differed between a societal, a healthcare system or a third-party payer perspective. The applied willingness-to-pay threshold ranged from 20,000 to 68,000 Great Britain pound sterling (GBP) per quality-adjusted life-year (QALY). FMT was considered the most cost-effective alternative in all studies. In five of the health economic evaluations, FMT was both more effective and cost saving than antibiotic treatment alternatives. The quality of the articles varied, and we identified several methodological concerns. Conclusions Economic evaluations consistently reported that FMT is a cost-effective and potentially cost-saving treatment for rCDI. Based on a comparison with recent evidence within the area, the multiple methodological concerns seem not to change this conclusion. Therefore, implementing FMT for rCDI in clinical practice should be strongly considered.

Sign in / Sign up

Export Citation Format

Share Document